F
Filippo Caraci
Researcher at University of Catania
Publications - 209
Citations - 8384
Filippo Caraci is an academic researcher from University of Catania. The author has contributed to research in topics: Medicine & Neuroprotection. The author has an hindex of 43, co-authored 177 publications receiving 6347 citations. Previous affiliations of Filippo Caraci include Health Science University & Autonomous University of Madrid.
Papers
More filters
Journal ArticleDOI
Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials.
Giuseppe Grosso,Andrzej Pajak,Stefano Marventano,Sabrina Castellano,Fabio Galvano,Claudio Bucolo,Filippo Drago,Filippo Caraci +7 more
TL;DR: Omega-3 PUFA resulted effective in RCTs on patients with bipolar disorder, whereas no evidence was found for those exploring their efficacy on depressive symptoms in young populations, perinatal depression, primary disease other than depression and healthy subjects.
Journal ArticleDOI
Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Associated with Neuronal Degeneration in Alzheimer's Brain
Andrea Caricasole,Agata Copani,Agata Copani,Filippo Caraci,Eleonora Aronica,Annemieke J. M. Rozemuller,Alessandra Caruso,Marianna Storto,Giovanni Gaviraghi,Georg C. Terstappen,Ferdinando Nicoletti +10 more
TL;DR: It is concluded that induction of DKK1 contributes to the pathological cascade triggered by β-amyloid and is critically involved in the process of tau phosphorylation.
Journal ArticleDOI
β-Amyloid Monomers Are Neuroprotective
Maria Laura Giuffrida,Filippo Caraci,Bruno Pignataro,Sebastiano Cataldo,Paolo De Bona,Valeria Bruno,Gemma Molinaro,Giuseppe Pappalardo,Angela Messina,Angelo Palmigiano,Domenico Garozzo,Ferdinando Nicoletti,Enrico Rizzarelli,Agata Copani,Agata Copani +14 more
TL;DR: Synthetic Aβ1-42 monomers support the survival of developing neurons under conditions of trophic deprivation and protect mature neurons against excitotoxic death, a process that contributes to the overall neurodegeneration associated with AD.
Journal ArticleDOI
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
TL;DR: In a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD-related brain dysfunction, usable before clinical onset.
Journal ArticleDOI
Depression and Alzheimer's disease: Neurobiological links and common pharmacological targets
TL;DR: The evidence on the common molecular pathways between depression and Alzheimer's disease is examined and these pathways are discussed as new pharmacological targets for the treatment of both major depression and Alzheimers disease.